EMERGENT BIOSOLUTIONS

Emergent BioSolutions Reports Financial Results For First Quarter 2022

28 4 2022 16:05:36 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022

08 4 2022 06:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Provides Corporate Governance Update

23 3 2022 16:05:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

14 3 2022 16:05:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning

11 3 2022 06:34:09 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021

24 2 2022 16:05:03 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022

07 2 2022 06:30:00 提供 Nasdaq GlobeNewswire

Founder and Executive Chairman of Emergent BioSolutions Announces Retirement

14 1 2022 06:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results

09 1 2022 14:00:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

03 1 2022 06:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate

16 12 2021 07:30:29 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces Stock Repurchase Program

11 11 2021 16:05:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results For Third Quarter 2021

04 11 2021 16:05:02 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021

18 10 2021 06:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP

15 10 2021 06:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

14 9 2021 08:00:02 提供 Nasdaq GlobeNewswire

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19

25 8 2021 06:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

23 8 2021 16:05:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results For Second Quarter 2021

29 7 2021 16:05:01 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility

29 7 2021 07:24:59 提供 Nasdaq GlobeNewswire